A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) (HALO)First published 22/11/2022 Last updated 14/03/2025 EU PAS number: EUPAS49827StudyOngoing